Fabiola Schafer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fabiola Schafer has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Rodrigo Miranda
School of Medicine, Faculty of Health Sciences and Center for Research, Innovation and Creation (CIIC), Universidad Católica de Temuco, Chile
5 shared publicationsEnrique Bellolio
Department of Pathological Anatomy, School of Medicine, Universidad de La Frontera, Temuco, Chile
4 shared publicationsMiguel Angel Villaseca
Department of Pathological Anatomy, School of Medicine, Universidad de La Frontera, Temuco, Chile
4 shared publications- Rodrigo Miranda
Department of Internal Medicine, School of Medicine, Universidad de La Frontera, Temuco, Chile
3 shared publications Cristian Pinto
Department of Medical Specialties, School of Medicine, Scientific and Technological Bioresources Nucleus (BIOREN), University of La Frontera, Temuco, Chile
2 shared publications- Enrique Bellolio
Department of Pathological Anatomy, School of Medicine Universidad de La Frontera Temuco Chile
2 shared publications
Latest Publications
- Open Access
- 8 January 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106, adv44513
Risk Factors for Melanoma Survival: DGCR8 as a Predictive Factor for Mortality in Young Patients
MicroRNA-processing enzymes – Dicer and DGCR8 – have been found to be dysregulated in melanoma. This study investigated whether these microRNA-processing enzymes could be used as risk factors for mortality. A retrospective cohort including medical history and samples of 74 patients was reviewed. Clinical and pathological variables were compared with mortality. Percentage of immunoreactive tumour cells (%IRC) for each enzyme was evaluated using immunohistochemistry. A dichotomous breakdown of DGCR8 and Dicer expression (negative or positive test) was performed using a cut-off of 80% IRC. The 5-year survival rate of stage 0–I–II was 89.5% and stage III–IV was 18.5%. In the bivariate analysis, variables associated with lower survival were: aged over 42 years, histologic subtypes, Breslow thickness ≥ 0.8mm, ulceration, vascular invasion, metastatic melanoma, positive sentinel node, more than 1 positive node, LDH > 200 IU/L, distant metastasis, and stage III–IV. In the multivariate Cox model, the analysis for stage III–IV showed a significantly lower survival curve in patients with a positive DGCR8 test and aged ≤ 42 years (p = 0.0152, Wald test). The Cox proportional hazards model showed that a positive DGCR8 test was a predictive factor for mortality in patients aged ≤ 42 years (HR = 14.3, 95%CI 1.5–140, p = 0.024). This study highlights a potential biomarker for melanoma survival and its utility in stratifying high-risk patients.
- 8 January 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106, adv44513
Open AccessRisk Factors for Melanoma Survival: DGCR8 as a Predictive Factor for Mortality in Young Patients
MicroRNA-processing enzymes – Dicer and DGCR8 – have been found to be dysregulated in melanoma. This study investigated whether these microRNA-processing enzymes could be used as risk factors for mortality. A retrospective cohort including medical history and samples of 74 patients was reviewed. Clinical and pathological variables were compared with mortality. Percentage of immunoreactive tumour cells (%IRC) for each enzyme was evaluated using immunohistochemistry. A dichotomous breakdown of DGCR8 and Dicer expression (negative or positive test) was performed using a cut-off of 80% IRC. The 5-year survival rate of stage 0–I–II was 89.5% and stage III–IV was 18.5%. In the bivariate analysis, variables associated with lower survival were: aged over 42 years, histologic subtypes, Breslow thickness ≥ 0.8mm, ulceration, vascular invasion, metastatic melanoma, positive sentinel node, more than 1 positive node, LDH > 200 IU/L, distant metastasis, and stage III–IV. In the multivariate Cox model, the analysis for stage III–IV showed a significantly lower survival curve in patients with a positive DGCR8 test and aged ≤ 42 years (p = 0.0152, Wald test). The Cox proportional hazards model showed that a positive DGCR8 test was a predictive factor for mortality in patients aged ≤ 42 years (HR = 14.3, 95%CI 1.5–140, p = 0.024). This study highlights a potential biomarker for melanoma survival and its utility in stratifying high-risk patients.
- 8 May 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (5) , e70110
Characteristics of the MicroRNA‐Processing Enzymes in Melanocytic Skin Lesions: Dicer and DGCR8 Are Potential Biomarkers for Primary Cutaneous Melanomas
Primary cutaneous melanoma (PCM) is an aggressive skin cancer. Its physiopathology is a challenge with heterogeneous pathways involved. As such, microRNA‐processing enzymes have been shown to be deregulated in cancer. The aim of this study was to characterise the expression profile of Dicer, Drosha, DGCR8 and PACT enzymes in melanocytic skin lesions. A total of 126 formalin‐fixed paraffin‐embedded samples, including 42 benign nevi, 42 dysplastic nevi and 42 PCM, were studied using tissue microarray and immunohistochemistry, which was graded based on the percentage of immunoreactive tumour cells (%IRC). Increased Dicer immunoexpression was found in PCM compared to benign nevi (p = 0.044) and increased DGCR8 immunoexpression was found in PCM compared to dysplastic and benign nevi (p = 0.000). For Drosha and PACT, only dysplastic nevi showed an increased expression (p = 0.011). A ROC curve cut‐off of 80% IRC was used. For Dicer, the specificity for non‐malignant cutaneous lesions (NMCL) was 98.8%, and sensitivity for PCM was 31.0%. The negative predictive value (NPV) was 98.6% and positive predictive value (PPV) was 34.7%. For DGCR8, the specificity for NMCL was 100%, and sensitivity for PCM was 31.0%. The NPV was 98.6% and PPV was 100%. All cases with positive Dicer and DGCR8 immunoexpression were melanomas. Dicer was increased in nodular histologic subtype (p = 0.011) and DGCR8 was higher in males (p = 0.005). Both Dicer and DGCR8 were increased in ulcerated PCM (p < 0.05). Dicer and DGCR8 play an important role in melanoma development with a potential use as diagnostic tools to differentiate PCM from other melanocytic skin lesions.
- 8 May 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (5) , e70110
Characteristics of the MicroRNA‐Processing Enzymes in Melanocytic Skin Lesions: Dicer and DGCR8 Are Potential Biomarkers for Primary Cutaneous Melanomas
Primary cutaneous melanoma (PCM) is an aggressive skin cancer. Its physiopathology is a challenge with heterogeneous pathways involved. As such, microRNA‐processing enzymes have been shown to be deregulated in cancer. The aim of this study was to characterise the expression profile of Dicer, Drosha, DGCR8 and PACT enzymes in melanocytic skin lesions. A total of 126 formalin‐fixed paraffin‐embedded samples, including 42 benign nevi, 42 dysplastic nevi and 42 PCM, were studied using tissue microarray and immunohistochemistry, which was graded based on the percentage of immunoreactive tumour cells (%IRC). Increased Dicer immunoexpression was found in PCM compared to benign nevi (p = 0.044) and increased DGCR8 immunoexpression was found in PCM compared to dysplastic and benign nevi (p = 0.000). For Drosha and PACT, only dysplastic nevi showed an increased expression (p = 0.011). A ROC curve cut‐off of 80% IRC was used. For Dicer, the specificity for non‐malignant cutaneous lesions (NMCL) was 98.8%, and sensitivity for PCM was 31.0%. The negative predictive value (NPV) was 98.6% and positive predictive value (PPV) was 34.7%. For DGCR8, the specificity for NMCL was 100%, and sensitivity for PCM was 31.0%. The NPV was 98.6% and PPV was 100%. All cases with positive Dicer and DGCR8 immunoexpression were melanomas. Dicer was increased in nodular histologic subtype (p = 0.011) and DGCR8 was higher in males (p = 0.005). Both Dicer and DGCR8 were increased in ulcerated PCM (p < 0.05). Dicer and DGCR8 play an important role in melanoma development with a potential use as diagnostic tools to differentiate PCM from other melanocytic skin lesions.
- Open Access
- 31 December 2024
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 31 (6) , 929-930
A giant seroma inducing changes in the position of the pacemaker
- 31 December 2024
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 31 (6) , 929-930
Open AccessA giant seroma inducing changes in the position of the pacemaker
- 27 January 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (6) , e209-e210
Anetoderma: Unusual clinical presentation of granuloma annulare
- 27 January 2024
- Published by Wiley in The Journal of Dermatology
- Vol. 51 (6) , e209-e210
Anetoderma: Unusual clinical presentation of granuloma annulare
- Open Access
- 22 January 2023
- Published by Wiley in Journal of Arrhythmia
- Vol. 39 (2) , 242-244
A cutaneous lesion mimicking pacemaker infection
- 22 January 2023
- Published by Wiley in Journal of Arrhythmia
- Vol. 39 (2) , 242-244
Open AccessA cutaneous lesion mimicking pacemaker infection
- Open Access
- 1 September 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 97 (5) , 682-683
Úlceras genitais agudas em jovem menina: desafio clínico
- 1 September 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 97 (5) , 682-683
Open AccessÚlceras genitais agudas em jovem menina: desafio clínico
- Open Access
- 13 July 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (5) , 682-683
Acute genital ulcers in a young girl: a clinical challenge: Lipschütz ulcer
- 13 July 2022
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 97 (5) , 682-683
Open AccessAcute genital ulcers in a young girl: a clinical challenge: Lipschütz ulcer
- Open Access
- 13 November 2020
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 39 (3) , 615-616
Acute onset of severe livedo reticularis in a patient with myocardial infarction
- 13 November 2020
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 39 (3) , 615-616
Open AccessAcute onset of severe livedo reticularis in a patient with myocardial infarction
- Open Access
- 8 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9) , 3327
Epigallocatechin Gallate Enhances MAL-PDT Cytotoxic Effect on PDT-Resistant Skin Cancer Squamous Cells
Photodynamic therapy (PDT) has been used to treat certain types of non-melanoma skin cancer with promising results. However, some skin lesions have not fully responded to this treatment, suggesting a potential PDT-resistant phenotype. Therefore, novel therapeutic alternatives must be identified that improve PDT in resistant skin cancer. In this study, we analyzed the cell viability, intracellular protoporphyrin IX (PpIX) content and subcellular localization, proliferation profile, cell death, reactive oxygen species (ROS) detection and relative gene expression in PDT-resistant HSC-1 cells. PDT-resistant HSC-1 cells show a low quantity of protoporphyrin IX and low levels of ROS, and thus a low rate of death cell. Furthermore, the resistant phenotype showed a downregulation of HSPB1, SLC15A2, FECH, SOD2 and an upregulation of HMBS and BIRC5 genes. On the other hand, epigallocatechin gallate catechin enhanced the MAL-PDT effect, increasing levels of protoporphyrin IX and ROS, and killing 100% of resistant cells. The resistant MAL-PDT model of skin cancer squamous cells (HSC-1) is a reliable and useful tool to understand PDT cytotoxicity and cellular response. These resistant cells were successfully sensitized with epigallocatechin gallate catechin. The in vitro epigallocatechin gallate catechin effect as an enhancer of MAL-PDT in resistant cells is promising in the treatment of difficult skin cancer lesions.
- 8 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9) , 3327
Open AccessEpigallocatechin Gallate Enhances MAL-PDT Cytotoxic Effect on PDT-Resistant Skin Cancer Squamous Cells
Photodynamic therapy (PDT) has been used to treat certain types of non-melanoma skin cancer with promising results. However, some skin lesions have not fully responded to this treatment, suggesting a potential PDT-resistant phenotype. Therefore, novel therapeutic alternatives must be identified that improve PDT in resistant skin cancer. In this study, we analyzed the cell viability, intracellular protoporphyrin IX (PpIX) content and subcellular localization, proliferation profile, cell death, reactive oxygen species (ROS) detection and relative gene expression in PDT-resistant HSC-1 cells. PDT-resistant HSC-1 cells show a low quantity of protoporphyrin IX and low levels of ROS, and thus a low rate of death cell. Furthermore, the resistant phenotype showed a downregulation of HSPB1, SLC15A2, FECH, SOD2 and an upregulation of HMBS and BIRC5 genes. On the other hand, epigallocatechin gallate catechin enhanced the MAL-PDT effect, increasing levels of protoporphyrin IX and ROS, and killing 100% of resistant cells. The resistant MAL-PDT model of skin cancer squamous cells (HSC-1) is a reliable and useful tool to understand PDT cytotoxicity and cellular response. These resistant cells were successfully sensitized with epigallocatechin gallate catechin. The in vitro epigallocatechin gallate catechin effect as an enhancer of MAL-PDT in resistant cells is promising in the treatment of difficult skin cancer lesions.
- 8 May 2014
- Published by Wiley in The Journal of Dermatology
- Vol. 41 (7) , 646-647
Giant congenital juvenile xanthogranuloma presenting as a yellowish atrophic plaque
- 8 May 2014
- Published by Wiley in The Journal of Dermatology
- Vol. 41 (7) , 646-647
Giant congenital juvenile xanthogranuloma presenting as a yellowish atrophic plaque